Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-07-25 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于控股股东之一致行动人股份减持计划的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a pre-disclosure announcement regarding a planned reduction in shareholding by a controlling shareholder's concert party. It details the shareholder's current holdings, the planned reduction amount, reasons for reduction, and compliance with regulatory requirements. The document does not contain financial statements or performance data but is an announcement about a shareholder's intention to reduce shares. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels.
2025-07-25 Chinese
关于创新药HSK47388片获得FDA同意开展临床试验的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding FDA approval to proceed with clinical trials for a new drug (HSK47388). It includes a description of the drug, regulatory approval status, and a risk warning to investors. There is no financial data, no mention of annual or quarterly results, no voting results, no management changes, and no detailed financial or governance information. The document is a regulatory announcement about a clinical trial approval, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-07-15 Chinese
关于变更保荐机构后重新签署募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the change of the sponsor institution and the re-signing of a tripartite supervision agreement for raised funds. It details the background of the fundraising, the status of the raised funds, the opening of special accounts, and the main contents of the supervision agreement. It does not contain financial statements or detailed financial performance data but rather regulatory and procedural information about the management and supervision of the raised funds. The document length is 4487 characters, which is relatively short and focused on an announcement. Therefore, it fits best as a Capital/Financing Update (CAP) since it relates to fundraising activities and the management of raised capital.
2025-07-13 Chinese
北京市中伦律师事务所关于海思科医药集团股份有限公司2025年度向特定对象发行A股股票的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a company's planned issuance of A shares to specific investors in 2025. It contains detailed legal review and confirmation of the company's qualifications, approvals, shareholder structure, related party transactions, assets, liabilities, and compliance with laws and regulations related to the share issuance. The document is not a financial report, earnings release, or management discussion, but a legal opinion supporting a capital raising event. This fits the category of Capital/Financing Update (CAP), as it relates to the company's fundraising activity and issuance of new shares to specific investors. The document length is substantial and contains detailed legal analysis, not just an announcement or certification, so it is not RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2025-07-07 Chinese
中信证券股份有限公司关于海思科医药集团股份有限公司向特定对象发行A股股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is a detailed underwriting and sponsorship letter for a specific issuance of A shares by Haisco Pharmaceutical Group Co., Ltd. It includes extensive company background, product descriptions, financial data, risk factors, issuance details, pricing, and use of proceeds. The document is titled as a "上市保荐书" (Listing Sponsorship Letter) related to a specific share issuance to particular investors. It is not a general annual or quarterly report, nor an earnings release or call transcript. It is not a proxy statement or voting results announcement. The document is a formal capital/financing update related to a share issuance, including details on the offering, pricing, investors, and use of proceeds. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full filing, not just an announcement or certification.
2025-07-07 Chinese
中信证券股份有限公司关于海思科医药集团股份有限公司向特定对象发行A股股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Sponsorship Letter) related to a specific issuance of A shares by 海思科医药集团股份有限公司 (Haisco Pharmaceutical Group Co., Ltd.). It is issued by 中信证券股份有限公司 (CITIC Securities) as the sponsor. The content includes detailed information about the securities issuance, the sponsor's commitments, the issuer's background, shareholding structure, financial data, and regulatory compliance references. The document is lengthy (15,000 characters) and contains substantive financial data and detailed descriptions of the issuance process, shareholder changes, and financial audits. This is not a simple announcement or a brief summary but a comprehensive sponsorship document related to a capital raising event. According to the filing definitions, updates on company fundraising or financing activities, including issuance sponsorship documents, fall under Capital/Financing Update (CAP). Therefore, this document is best classified as a Capital/Financing Update (CAP).
2025-07-07 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.